Galmed Pharmaceuticals Ltd. (GLMD) Form 6-K — Jul 31, 2026

Galmed Pharmaceuticals received a notification from Nasdaq granting an additional 180 calendar day period, or until January 25, 2027, to regain compliance with the minimum $1.00 bid price requirement. This extension follows the company's failure to meet the listing requirement during the initial 180-day cure period that ended on July 28, 2026. The company was first notified of the bid price deficiency on January 29, 2026, after failing to maintain a closing bid price of $1.00 or more for 30 consecutive trading days. To regain compliance, Galmed's ordinary shares must close at or above $1.00 per share for a minimum of 10 consecutive trading days before the new deadline.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.